Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of March 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 5,662,569,783 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,188,375,625.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports the static capital position as of March 31, 2009, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under the Financial Services Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,188,375,625) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (474,194,158) to understand the float.
- Check subsequent filings for financial performance data, as this 6-K contains no operational or financial results.